ArticleVeterinary and animal science2026

Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis.

Hilde Moyaert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.